CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y Xiao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Interleukins in cancer: from biology to therapy
Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …
Transfer learning enables predictions in network biology
Mapping gene networks requires large amounts of transcriptomic data to learn the
connections between genes, which impedes discoveries in settings with limited data …
connections between genes, which impedes discoveries in settings with limited data …
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
The use of lipid-formulated RNA vaccines for cancer or COVID-19 is associated with dose-
limiting systemic inflammatory responses in humans that were not predicted from preclinical …
limiting systemic inflammatory responses in humans that were not predicted from preclinical …
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
JH Park, K Nath, SM Devlin, CS Sauter, ML Palomba… - Nature medicine, 2023 - nature.com
In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune
effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 …
effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Cytokine storm in COVID-19: immunopathogenesis and therapy
C Zanza, T Romenskaya, AC Manetti, F Franceschi… - Medicina, 2022 - mdpi.com
A cytokine storm is a hyperinflammatory state secondary to the excessive production of
cytokines by a deregulated immune system. It manifests clinically as an influenza-like …
cytokines by a deregulated immune system. It manifests clinically as an influenza-like …